NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): AN ECONOMIC ANALYSIS

被引：0
|
作者：
Spigel, David [1 ]
Harwin, William [2 ]
Dranitsaris, George [3 ]
Binder, Gary [4 ]
Weber, Paul [4 ]
Renschler, Markus F. [4 ]
Socinski, Mark A. [5 ]
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Augmentium Pharma Consulting, Toronto, ON, Canada
[4] Celgene Corp, Berkeley Hts, NJ USA
[5] Univ Pittsburgh, Pittsburgh, PA 15260 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
economic analysis; nab-Paclitaxel; non-small cell lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.10-043
引用
收藏
页码：S1176 / S1177
页数：2
相关论文
共 50 条
  • [1] NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN DIABETIC PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Hirsh, Vera
    Owen, Scott
    Ko, Amy
    Renschler, Markus F.
    Socinski, Mark A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S584 - S584
  • [2] NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSIS OF PREDICTIVE FACTORS
    Hirsh, Vera
    Page, Ray
    Ko, Amy
    Renschler, Markus F.
    Socinski, Mark A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S879 - S879
  • [3] NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSIS OF PERIPHERAL NEUROPATHY
    Sakai, Hiroshi
    Ko, Amy
    Renschler, Markus F.
    Socinski, Mark A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S569 - S570
  • [4] Weekly nab®-Paclitaxel In Combination With Carboplatin As First-line Therapy In Elderly Patients (pts) With Advanced Non-small Cell Lung Cancer (nsclc)
    Socinski, M. A.
    Langer, C. J.
    Okamoto, I.
    Hon, J. K.
    Hirsh, V.
    Dakhil, S. R.
    Page, R. D.
    Orsini, J.
    Zhang, H.
    Renschler, M. F.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S215 - S215
  • [5] Weekly nab -paclitaxel in combination with carboplatin as first-line therapy in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Socinski, Mark A.
    Langer, Corey J.
    Okamoto, Isamu
    Hon, Jeremy K.
    Hirsh, Vera
    Dakhil, Shaker R.
    Page, Ray D.
    Orsini, James M.
    Zhang, Hui
    Renschler, Markus F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC)
    Hawkins, M. J.
    Manikhas, G.
    Makhson, A.
    Cheporov, S.
    Orlov, S.
    Yablonsky, P.
    Bhar, P.
    Socinski, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first- line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Renschler, Markus Frederic
    Okamoto, Isamu
    Hon, Jeremy K.
    Hirsh, Vera
    Dakhil, Shaker R.
    Page, Ray D.
    Orsini, James
    Zhang, Hui
    Socinski, Mark A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Weekly nab®-Paclitaxel in Combination with Carboplatin as First-line Therapy in Pts (pts) with Advanced Non-small Cell Lung Cancer (NSCLC): Analysis of Safety and Efficacy in Pts with Renal Impairment
    Hon, J. K.
    Okamoto, I.
    Hirsh, V.
    Dakhil, S. R.
    Page, R. D.
    Orsini, J.
    Zhang, H.
    Renschler, M. F.
    Socinski, M. A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S245 - S245
  • [9] nab®-Paclitaxel in Combination with Carboplatin as First-line Therapy in Patients (pts) with Advanced Non-small Cell Lung Cancer (NSCLC): Analysis of Pt Characteristics and Clinical Treatment Patterns by Region
    Socinski, M.
    Okamoto, I.
    Hon, J. K.
    Hirsh, V.
    Dakhil, S. R.
    Page, R. D.
    Orsini, J.
    Zhang, H.
    Renschler, M. F.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S242 - S243
  • [10] Analysis of Predictive Factors in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) as First-Line Therapy for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Hirsh, V.
    Page, R. D.
    Ko, A.
    Renshler, M.
    Socinski, M. A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S43 - S43
12345